NYSE · CIK 0001999480
ANRO Alto Neuroscience, Inc.
Insider trading from SEC Form 4. Last filing 7 d ago. Close $24.37 on Oct 9, 2026, +334% from the 52-week low and -33% from the high.
Last 90 days
Net insider value
-$3.6M
more sold than bought
Buys
0
$0 by 0 insiders
Sells
1
$3.6M by 1 insider
Insiders on file
9
with a Form 4 at this company
Price and insider trades, last year
ANROOct 9, 2026 · close 24.37
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Alto Neuroscience, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 32Weak | Nicholas Conrad Smith PRESIDENT AND CFO sell | $3.6M 134,886 shares | -100% | - |
Transactions
The last 58 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 2, 2026 | Nicholas Conrad Smith PRESIDENT AND CFO | MOption exercise Common Stock | +55,000 | $2.32 | $128k | 79,060 | 7 d ago |
| Oct 2, 2026 | Nicholas Conrad Smith PRESIDENT AND CFO | MOption exercise Employee Stock Option (Right to Buy)derivative | -55,000 | $0.00 | $0 | 57,405 | 7 d ago |
| Sep 29, 2026 | Nicholas Conrad Smith PRESIDENT AND CFO | MOption exercise Common Stock10b5-1 | +56,455 | $2.35 | $133k | 80,515 | 11 d ago |
| Sep 29, 2026 | Nicholas Conrad Smith PRESIDENT AND CFO | MOption exercise Common Stock10b5-1 | +54,375 | $2.35 | $128k | 134,890 | 11 d ago |
| Sep 29, 2026 | Nicholas Conrad Smith PRESIDENT AND CFO | SOpen-market sale Common Stock10b5-1 | -110,830 | $26.58 | $2.9M | 24,060 | 11 d ago |
| Sep 30, 2026 | Nicholas Conrad Smith PRESIDENT AND CFO | MOption exercise Common Stock10b5-1 | +24,056 | $2.35 | $57k | 48,116 | 11 d ago |
| Sep 30, 2026 | Nicholas Conrad Smith PRESIDENT AND CFO | SOpen-market sale Common Stock10b5-1 | -23,170 | $25.78 | $597k | 24,946 | 11 d ago |
| Sep 30, 2026 | Nicholas Conrad Smith PRESIDENT AND CFO | SOpen-market sale Common Stock10b5-1 | -886 | $26.87 | $24k | 24,060 | 11 d ago |
| Sep 29, 2026 | Nicholas Conrad Smith PRESIDENT AND CFO | MOption exercise Employee Stock Option (Right to Buy)derivative10b5-1 | -56,455 | $0.00 | $0 | 145,874 | 11 d ago |
| Sep 29, 2026 | Nicholas Conrad Smith PRESIDENT AND CFO | MOption exercise Employee Stock Option (Right to Buy)derivative10b5-1 | -54,375 | $0.00 | $0 | 35,625 | 11 d ago |
| Sep 30, 2026 | Nicholas Conrad Smith PRESIDENT AND CFO | MOption exercise Employee Stock Option (Right to Buy)derivative10b5-1 | -24,056 | $0.00 | $0 | 121,818 | 11 d ago |
| Aug 12, 2025 | Ramiro Sanchez director | AGrant or award Stock Option (right to buy)derivative | +30,574 | $0.00 | $0 | 30,574 | Aug 14, 2025 |
| Aug 12, 2025 | Ramiro Sanchez director | AGrant or award Stock Option (right to buy)derivative | +3,928 | $2.21 | $8,681 | 3,928 | Aug 14, 2025 |
| Jul 3, 2025 | Michael Conick Hanley Jr. CHIEF OPERATING OFFICER | AGrant or award Employee Stock Option (Right to Buy)derivative | +8,000 | - | - | 8,000 | Jul 8, 2025 |
| Jul 3, 2025 | Adam Savitz CHIEF MEDICAL OFFICER | AGrant or award Employee Stock Option (Right to Buy)derivative | +22,481 | - | - | 22,481 | Jul 8, 2025 |
| Jul 3, 2025 | Amit Etkin PRESIDENT AND CEO | AGrant or award Employee Stock Option (Right to Buy)derivative | +34,620 | - | - | 34,620 | Jul 8, 2025 |
| Jul 3, 2025 | Nicholas Conrad Smith CHIEF FINANCIAL OFFICER & CBO | AGrant or award Employee Stock Option (Right to Buy)derivative | +44,962 | - | - | 44,962 | Jul 8, 2025 |
| Jul 3, 2025 | Amit Etkin PRESIDENT AND CEO | DDisposition to issuer Employee Stock Option (Right to Buy)derivative | -34,620 | - | - | 0 | Jul 8, 2025 |
| Jul 3, 2025 | Adam Savitz CHIEF MEDICAL OFFICER | DDisposition to issuer Employee Stock Option (Right to Buy)derivative | -22,481 | - | - | 0 | Jul 8, 2025 |
| Jul 3, 2025 | Nicholas Conrad Smith CHIEF FINANCIAL OFFICER & CBO | DDisposition to issuer Employee Stock Option (Right to Buy)derivative | -44,962 | - | - | 0 | Jul 8, 2025 |
| Jul 3, 2025 | Michael Conick Hanley Jr. CHIEF OPERATING OFFICER | DDisposition to issuer Employee Stock Option (Right to Buy)derivative | -8,000 | - | - | 0 | Jul 8, 2025 |
| Jul 3, 2025 | Adam Savitz CHIEF MEDICAL OFFICER | AGrant or award Employee Stock Option (Right to Buy)derivative | +33,008 | - | - | 33,008 | Jul 8, 2025 |
| Jul 3, 2025 | Michael Conick Hanley Jr. CHIEF OPERATING OFFICER | AGrant or award Employee Stock Option (Right to Buy)derivative | +188,000 | - | - | 188,000 | Jul 8, 2025 |
| Jul 3, 2025 | Nicholas Conrad Smith CHIEF FINANCIAL OFFICER & CBO | AGrant or award Employee Stock Option (Right to Buy)derivative | +33,833 | - | - | 33,833 | Jul 8, 2025 |
| Jul 3, 2025 | Amit Etkin PRESIDENT AND CEO | AGrant or award Employee Stock Option (Right to Buy)derivative | +247,290 | - | - | 247,290 | Jul 8, 2025 |
| Jul 3, 2025 | Nicholas Conrad Smith CHIEF FINANCIAL OFFICER & CBO | DDisposition to issuer Employee Stock Option (Right to Buy)derivative | -33,833 | - | - | 0 | Jul 8, 2025 |
| Jul 3, 2025 | Adam Savitz CHIEF MEDICAL OFFICER | DDisposition to issuer Employee Stock Option (Right to Buy)derivative | -33,008 | - | - | 0 | Jul 8, 2025 |
| Jul 3, 2025 | Michael Conick Hanley Jr. CHIEF OPERATING OFFICER | DDisposition to issuer Employee Stock Option (Right to Buy)derivative | -188,000 | - | - | 0 | Jul 8, 2025 |
| Jul 3, 2025 | Amit Etkin PRESIDENT AND CEO | DDisposition to issuer Employee Stock Option (Right to Buy)derivative | -247,290 | - | - | 0 | Jul 8, 2025 |
| Jul 3, 2025 | Nicholas Conrad Smith CHIEF FINANCIAL OFFICER & CBO | AGrant or award Employee Stock Option (Right to Buy)derivative | +202,329 | - | - | 202,329 | Jul 8, 2025 |
| Jul 3, 2025 | Adam Savitz CHIEF MEDICAL OFFICER | AGrant or award Employee Stock Option (Right to Buy)derivative | +123,645 | - | - | 123,645 | Jul 8, 2025 |
| Jul 3, 2025 | Amit Etkin PRESIDENT AND CEO | AGrant or award Employee Stock Option (Right to Buy)derivative | +223,000 | - | - | 223,000 | Jul 8, 2025 |
| Jul 3, 2025 | Michael Conick Hanley Jr. CHIEF OPERATING OFFICER | AGrant or award Employee Stock Option (Right to Buy)derivative | +125,000 | - | - | 125,000 | Jul 8, 2025 |
| Jul 3, 2025 | Amit Etkin PRESIDENT AND CEO | DDisposition to issuer Employee Stock Option (Right to Buy)derivative | -223,000 | - | - | 0 | Jul 8, 2025 |
| Jul 3, 2025 | Michael Conick Hanley Jr. CHIEF OPERATING OFFICER | DDisposition to issuer Employee Stock Option (Right to Buy)derivative | -125,000 | - | - | 0 | Jul 8, 2025 |
| Jul 3, 2025 | Nicholas Conrad Smith CHIEF FINANCIAL OFFICER & CBO | DDisposition to issuer Employee Stock Option (Right to Buy)derivative | -202,329 | - | - | 0 | Jul 8, 2025 |
| Jul 3, 2025 | Adam Savitz CHIEF MEDICAL OFFICER | DDisposition to issuer Employee Stock Option (Right to Buy)derivative | -123,645 | - | - | 0 | Jul 8, 2025 |
| Jul 3, 2025 | Amit Etkin PRESIDENT AND CEO | AGrant or award Employee Stock Option (Right to Buy)derivative | +215,000 | - | - | 215,000 | Jul 8, 2025 |
| Jul 3, 2025 | Adam Savitz CHIEF MEDICAL OFFICER | AGrant or award Employee Stock Option (Right to Buy)derivative | +73,000 | - | - | 73,000 | Jul 8, 2025 |
| Jul 3, 2025 | Nicholas Conrad Smith CHIEF FINANCIAL OFFICER & CBO | AGrant or award Employee Stock Option (Right to Buy)derivative | +90,000 | - | - | 90,000 | Jul 8, 2025 |
| Jul 3, 2025 | Amit Etkin PRESIDENT AND CEO | DDisposition to issuer Employee Stock Option (Right to Buy)derivative | -215,000 | - | - | 0 | Jul 8, 2025 |
| Jul 3, 2025 | Nicholas Conrad Smith CHIEF FINANCIAL OFFICER & CBO | DDisposition to issuer Employee Stock Option (Right to Buy)derivative | -90,000 | - | - | 0 | Jul 8, 2025 |
| Jul 3, 2025 | Adam Savitz CHIEF MEDICAL OFFICER | DDisposition to issuer Employee Stock Option (Right to Buy)derivative | -73,000 | - | - | 0 | Jul 8, 2025 |
| Jul 3, 2025 | Adam Savitz CHIEF MEDICAL OFFICER | AGrant or award Employee Stock Option (Right to Buy)derivative | +76,000 | - | - | 76,000 | Jul 8, 2025 |
| Jul 3, 2025 | Nicholas Conrad Smith CHIEF FINANCIAL OFFICER & CBO | AGrant or award Employee Stock Option (Right to Buy)derivative | +135,000 | - | - | 135,000 | Jul 8, 2025 |
| Jul 3, 2025 | Adam Savitz CHIEF MEDICAL OFFICER | DDisposition to issuer Employee Stock Option (Right to Buy)derivative | -76,000 | - | - | 0 | Jul 8, 2025 |
| Jul 3, 2025 | Nicholas Conrad Smith CHIEF FINANCIAL OFFICER & CBO | DDisposition to issuer Employee Stock Option (Right to Buy)derivative | -135,000 | - | - | 0 | Jul 8, 2025 |
| May 13, 2025 | Andrew Dreyfus director | AGrant or award Stock Option (right to buy)derivative | +15,287 | $0.00 | $0 | 15,287 | May 15, 2025 |
| May 13, 2025 | Husseini Manji director | AGrant or award Stock Option (right to buy)derivative | +15,287 | $0.00 | $0 | 15,287 | May 15, 2025 |
| May 13, 2025 | Christopher Nixon Cox director | AGrant or award Stock Option (right to buy)derivative | +15,287 | $0.00 | $0 | 15,287 | May 15, 2025 |
| May 13, 2025 | Gwill York director | AGrant or award Stock Option (right to buy)derivative | +15,287 | $0.00 | $0 | 15,287 | May 15, 2025 |
| Feb 5, 2025 | Amit Etkin PRESIDENT AND CEO | AGrant or award Employee Stock Option (Right to Buy)derivative | +215,000 | $0.00 | $0 | 215,000 | Feb 7, 2025 |
| Feb 5, 2025 | Adam Savitz CHIEF MEDICAL OFFICER | AGrant or award Employee Stock Option (Right to Buy)derivative | +76,000 | $0.00 | $0 | 76,000 | Feb 7, 2025 |
| Feb 5, 2025 | Nicholas Conrad Smith CHIEF FINANCIAL OFFICER & CBO | AGrant or award Employee Stock Option (Right to Buy)derivative | +135,000 | $0.00 | $0 | 135,000 | Feb 7, 2025 |
| Feb 5, 2025 | Michael Conick Hanley Jr. CHIEF OPERATING OFFICER | AGrant or award Employee Stock Option (Right to Buy)derivative | +125,000 | $0.00 | $0 | 125,000 | Feb 7, 2025 |
| Jan 2, 2025 | Christopher Nixon Cox director | AGrant or award Stock Option (right to buy)derivative | +25,236 | $3.17 | $80k | 25,236 | Jan 6, 2025 |
| Jan 2, 2025 | Husseini Manji director | AGrant or award Stock Option (right to buy)derivative | +14,195 | $3.17 | $45k | 14,195 | Jan 6, 2025 |
| Jan 2, 2025 | Gwill York director | AGrant or award Stock Option (right to buy)derivative | +19,558 | $3.17 | $62k | 19,558 | Jan 6, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Christopher Nixon Coxdirector
- Andrew Dreyfusdirector
- Amit EtkinPRESIDENT AND CEO
- Michael Conick Hanley Jr.CHIEF OPERATING OFFICER
- Husseini Manjidirector
- Ramiro Sanchezdirector
- Adam SavitzCHIEF MEDICAL OFFICER
- Nicholas Conrad SmithCHIEF FINANCIAL OFFICER & CBO
- Gwill Yorkdirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.